Centessa Pharmaceuticals (STU:260) LT-Debt-to-Total-Asset : 0.21 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Centessa Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.21.

Centessa Pharmaceuticals's long-term debt to total assets ratio increased from Jun. 2023 (0.21) to Jun. 2024 (0.21). It may suggest that Centessa Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Centessa Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Centessa Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals LT-Debt-to-Total-Asset Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.12

0.16

0.24

Centessa Pharmaceuticals Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial											0.21	0.22	0.24	0.26	0.21

Centessa Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Centessa Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	77.567	/	330.346
	=	0.23

Centessa Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	79.054	/	370.527
	=

Centessa Pharmaceuticals (STU:260) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Centessa Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CNTA:USA 260:Germany

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals Headlines

No Headlines